Svar Life Science

July 3, 2023

PRESS RELEASE: Svar Life Science adopts Olink’s Novel Proteomics Solutions Technology to strengthen position as a Biomarker Discovery Services partner

Malmö, Sweden (July 3, 2023) - Svar Life Science today announced the adoption of a new advanced technology to enable the use of the Olink® high-throughput proteomics platform together with Svar CRO and its Biomarker Discovery Services.

The integration of Olink’s Novel Proteomics Solutions Technology will initially leverage high-throughput multiplex biomarker analysis to provide Svars' clients with specific, precise, high-sensitivity protein analysis to accelerate successful drug development.

Read Press Release

July 3, 2023

PRESS RELEASE: Svar Life Science adopts Olink’s Novel Proteomics Solutions Technology to strengthen position as a Biomarker Discovery Services partner

Malmö, Sweden (July 3, 2023) - Svar Life Science today announced the adoption of a new advanced technology to enable the use of the Olink® high-throughput proteomics platform together with Svar CRO and its Biomarker Discovery Services.

The integration of Olink’s Novel Proteomics Solutions Technology will initially leverage high-throughput multiplex biomarker analysis to provide Svars' clients with specific, precise, high-sensitivity protein analysis to accelerate successful drug development.

Read Press Release

Svar Life Science adopts Olink’s novel proteomics solutions technology to strengthen its position as a Biomarker Discovery Service partner and is the first CRO in the south of Sweden to offer the Olink® Proximity Extension Assay (PEA) technology for sample testing. The integration of the Olink® Signature Q100 instrument with the Olink® Target 96, Target 48, and Olink® Flex offering will allow Svar CRO Services to support even more biomarker discovery projects than before.

“We are excited to work with a leading, well-respected life science company like Olink. They have a great reputation for bringing flexible, scalable proteomics to the market,” said Anne Thjømøe, CEO of Svar Life Science. “Their Proteomics Solutions will help us support clients and drive the development of better, more targeted therapies and deliver new solutions tailored to customer requirements.”

“We are pleased to work together with Svar Life Science as it will further enhance the accessibility of the Olink proteomics platform to the scientific community. This aligns very nicely with our mission of accelerating research, better understanding of disease, more efficient and safer drug development, and enablement of earlier and more accurate diagnoses,” said Henk Mouthaan, Vice President Sales and Marketing EMEA, Olink.
“This technology expansion exemplifies how we work together with innovative companies to strengthen our capabilities and support researchers and drug development clients throughout the life science value chain,” notes Frida Pauly, Director Business Development at Svar. “By combining our CRO Service expertise with Olink’s unique and industry-leading proteomics technology platform, we will be able to offer integrated capabilities for enhanced biomarker discovery services, providing customers with more options in choosing an analytical platform that is optimal for their needs,” continues Frida Pauly.
 
Earlier this year, Svar expanded their CRO Service offering with QC testing services and have since been able to provide clients with biologics testing capacity such as:
  • Potency measurements of drug product and/or drug substance using cell-based assays for qualification or validation
  • Lot release support, as well as stability, and in-process analysis through routine testing of drug product and drug substance samples
“Now also being able to offer exploratory biomarker discovery services of the highest quality standards by once again investing in best-in-class platforms, expanding our service portfolio and bringing great value to all our existing and future customers,” said Filiz Ibraimi, COO at Svar Life Science.
Learn more about Svar Biomarker Discovery Services

About Olink PEA technology

The Olink technology allows for high throughput screening and detection of large numbers of proteins in small amounts of biological samples, such as blood, plasma and CSF. The Olink

The Olink panels for targeted protein biomarker discovery enable faster, better-informed decisions in human protein biomarker research by providing high-multiplex immunoassays benefits without compromising data quality or performance.
Learn more about Olink's PEA technology

About Olink

Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.